Related Experiment Video

Updated: Jan 3, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.5K

TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway

Man Zhu1, Liu Yang1, Xianpeng Shi1

  • 1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.

Journal of Cellular and Molecular Medicine
|November 20, 2019
PubMed

Insights

TPD7, a novel drug, effectively inhibits cutaneous T cell lymphoma by targeting the IL-2R pathway. This leads to apoptosis and cell cycle arrest, showing TPD7

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • The Interleukin-2 Receptor (IL-2R) pathway is crucial for immune cell development and a target for cancer therapy.
  • A lack of effective IL-2R inhibitors limits its therapeutic application.
  • TPD7, a novel biphenyl urea taspine derivative, exhibits anti-cancer properties.

Purpose of the Study:

  • To evaluate the anti-cancer activity of TPD7 in cutaneous T cell lymphoma (CTCL).
  • To elucidate the mechanism of TPD7 action via the IL-2R signaling pathway.

Main Methods:

  • Correlation analysis between TPD7's inhibitory effect and IL-2R expression.
  • Assessment of TPD7 binding to IL-2R and its effect on IL-2R mRNA and protein levels.
  • Investigation of TPD7's impact on downstream IL-2R signaling cascades (JAK/STAT, PI3K/AKT/mTOR, PLCγ/Raf/MAPK).
  • Flow cytometry analysis to evaluate apoptosis and cell cycle progression.

Main Results:

  • TPD7 demonstrated significant anti-cancer activity in CTCL cell lines, particularly H9 and HUT78.
  • TPD7 directly bound to IL-2R, down-regulating its expression at both mRNA and protein levels.
  • TPD7 suppressed key downstream signaling pathways, induced apoptosis via the Bcl-2 mitochondrial pathway, and caused G2/M cell cycle arrest.

Conclusions:

  • TPD7 is a potent anti-cancer agent with potential for CTCL treatment.
  • TPD7 exerts its therapeutic effects by modulating the IL-2R signaling pathway.
  • Further investigation of TPD7 as a therapeutic candidate for CTCL is warranted.
Keywords:
H9IL-2RTPD7cell growthcutaneous T cell lymphoma

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.4K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.6K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.3K